^
Association details:
| Biomarker: | BRCA2 mutation + TP53 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Regimen: | Modified FOLFOX6 (oxaliplatin + 5-fluorouracil + leucovorin calcium) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy
Published date:
03/02/2021
Excerpt:
All CRC cases were at pathological stage III and were treated with standard surgical resection followed by adjuvant chemotherapy with the mFOLFOX6 regimen (5-fluorouracil, leucovorin, and oxaliplatin)….Based on mutations in DDR genes (Fig. 3), we found co-occurrence of BRCA2 and TP53 somatic mutations to be associated with a poor prognosis. The median survival duration was 26.9 months.
DOI:
10.1186/s12885-021-07926-1
